“First quarter 2026 was a defining quarter for Agenus (AGEN) and for BOT and BAL,” said Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. “We saw continued physician requests and engagement treating patients with BOT and BAL through regulatory-authorized access pathways. Additionally, we advanced the program into Phase 3 enrollment and closed a transformative collaboration with Zydus that secured both capital and U.S. manufacturing capacity. BOT+BAL’s maturing data, particularly the durability of survival outcomes in refractory MSS colorectal cancer, continue to underpin our regulatory submissions in the United States and Europe.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- AGEN Earnings this Week: How Will it Perform?
- Agenus appoints BAP Pharma as global partner for BOT+BAL access programs
- Agenus reports Phase 2 results from BOT and BAL with agenT-797
- Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL
- Agenus: Strengthening Bot/Bal Clinical Profile and Capital-Efficient Path to Registration Underpin Positive Rating